Bill Corr to Kick Off Conference 30 Years After Passage of Orphan Drug Act
Bill Corr, deputy secretary of the U.S. Department of Health and Human Services, will deliver the keynote address at the third annual U.S. Conference on Rare Diseases and Orphan Products in Bethesda, Md., on Oct. 7, 2013.
Corr was vital in the passage of the Orphan Drug Act (ODA), serving as counsel to the U.S. House of Representatives’ Subcommittee on Health and the Environment during the ODA hearings in 1983. In his leadership role at the U.S. Department of Health and Human Services, he is responsible for the operations of the largest civilian department in the federal government that is dedicated to protecting the health of all Americans.
“With this year marking the 30th anniversary of the Orphan Drug Act, we are honored to have someone of Deputy Secretary Corr’s stature and historical import deliver the keynote address,” said Susan Cantrell, director of DIA North America. “His unique perspective on how far we’ve come in the development of orphan products, and where we need to go, will set the tone for collaboration across disciplines to advance rare disease care.”
The conference is co-sponsored by the National Organization for Rare Disorders (NORD) and DIA in collaboration with the Food and Drug Administration and EURORDIS
(Rare Diseases Europe).
The conference will take place Oct. 7 to 9 at the Bethesda North Marriott Hotel & Conference Center, featuring plenary and group sessions focusing on topics such as the investment outlook, legislative updates and scientific advances.
A limited number of scholarships will be available to representatives of qualifying patient organizations that wish to participate in the conference. This scholarship program is supported by a grant from the Medtronic Foundation. NORD and DIA will conduct a complimentary pre-conference workshop for patient representatives on Oct. 6. Click here
to learn how patient organizations can participate.
Click here for more information on the U.S. Conference on Rare Diseases and Orphan Products.
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.
ABOUT NORD: NORD is a nonprofit organization established in 1983 by rare-disease patient organization leaders to represent all Americans affected by rare diseases. NORD provides programs of advocacy, education, research and patient/family services. It works closely with approximately 200 member organizations representing people with specific rare diseases. NORD has offices in Boston; Danbury, Conn.; and Washington, D.C. Learn more about NORD at www.rarediseases.org. Follow NORD on LinkedIn, Twitter, YouTube and Facebook.